Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

~20 mi. (Torrejón de Ardoz, Spain, +118 more cities)

Regeneron Research Facility

Skin Squamous Cell Carcinoma

cemiplimab

immunotherapy

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~34 mi. (Madrid, Spain, +192 more cities)

Hospital Universitario Ramón y Cajal

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~34 mi. (Madrid, Spain, +176 more cities)

Clinica Universitaria de Navarra ( Site 2181)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~34 mi. (Madrid, Spain, +89 more cities)

Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1320)

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~34 mi. (Madrid, Spain, +207 more cities)

Hospital General Universitario Gregorio Maranon ( Site 1367)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~34 mi. (Madrid, Spain, +159 more cities)

Hospital Universitario Ramon y Cajal ( Site 0660)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

~34 mi. (Madrid, Spain, +163 more cities)

Investigational Site Number :7240106

CEACAM5 Expression

Non-Squamous Non-Small Cell Lung Carcinoma

tusamitamab ravtansine

chemotherapy, +1 more type

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

~34 mi. (Madrid, Spain, +96 more cities)

Hospital Universitario 12 de Octubre, +3 more facilities

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

~34 mi. (Madrid, Spain, +69 more cities)

Hospital Universitario La Paz, +1 more facility

Cervical Adenocarcinoma, +2 more conditions

tisotumab vedotin

chemotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

~34 mi. (Madrid, Spain, +143 more cities)

Hospital Universitario Ramón y Cajal

RET Mutation

Thyroid Gland Medullary Carcinoma

selpercatinib

targeted therapy

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

~34 mi. (Madrid, Spain, +32 more cities)

Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)

ER Negative, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +12 more conditions

cisplatin, +4 more drugs

chemotherapy, +2 more types

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

~34 mi. (Madrid, Spain, +120 more cities)

Hospital Universitario 12 de Octubre, +5 more facilities

FGFR3 A391E, +9 more biomarkers

Urothelial Carcinoma

infigratinib

targeted therapy